摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-溴-4-氯-2-(甲基磺酰基)喹唑啉 | 1003043-76-2

中文名称
6-溴-4-氯-2-(甲基磺酰基)喹唑啉
中文别名
——
英文名称
6-bromo-4-chloro-2-(methylsulfanyl)quinazoline
英文别名
6-bromo-4-chloro-2-(methylthio)quinazoline;6-bromo-4-chloro-2-methylsulfanylquinazoline
6-溴-4-氯-2-(甲基磺酰基)喹唑啉化学式
CAS
1003043-76-2
化学式
C9H6BrClN2S
mdl
——
分子量
289.583
InChiKey
JVOCVKFAENOWJO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    124 °C
  • 沸点:
    438.8±48.0 °C(Predicted)
  • 密度:
    1.76±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    51.1
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090

SDS

SDS:2d59f13badbc3879cf583ba065b0703d
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] GABAa RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS GABAA
    申请人:FORSKARPATENT I SYD AB
    公开号:WO2009123537A1
    公开(公告)日:2009-10-08
    the resent invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABAA receptor modulator.
    这项最新的发明涉及具有广谱公式(I)的新化合物,具有镇静、抗惊厥、催眠-催眠和肌肉松弛条件,以及作为GABAA受体调节剂的哺乳动物,包括人类,具有焦虑、催眠和癫痫症状。
  • 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS
    申请人:Gao Ling-Jie
    公开号:US20090285782A1
    公开(公告)日:2009-11-19
    This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R 2 is hydrogen, NR′R″, C 1-7 alkyl, arylC 1-7 alkyl or C 3-10 cycloalkyl; R 4 is amino, C 1-7 alkyl, C 2-7 alkenyl, C 3-10 cycloalkyl, C 3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted C 1-7 alkyl or C 3-10 cycloalkyl-C 1-7 alkyl; R 5 is hydrogen or C 1-7 alkyl, or R 5 and R 4 together with the nitrogen atom to which they are attached form a heterocyclic ring; Y is a single bond, C 1-7 alkylene, C 2-7 alkenylene or C 2-7 alkynylene; R 6 is halogen, heteroaryl or aryl; R′ and R″ are each independently hydrogen, C 1-7 alkyl-carbonyl or C 1-7 alkyl; provided that R 4 is not phenyl substituted with morpholino when R 2 is H and R 5 is H, and provided that when NR 4 R 5 is piperazinyl, said NR 4 R 5 is either non-substituted or substituted with methyl or acetyl; a pharmaceutically acceptable addition salt, a stereoisomer, a mono- or a di-N-oxide, a solvate or a pro-drug thereof, for the treatment of viral infections.
    该发明提供了由结构式(I)表示的喹唑啉衍生物;其中:R2是氢、NR′R″、C1-7烷基、芳基C1-7烷基或C3-10环烷基;R4是氨基、C1-7烷基、C2-7烯基、C3-10环烷基、C3-10环烯基、芳基、杂环、芳基烷基、杂环取代的C1-7烷基或C3-10环烷基-C1-7烷基;R5是氢或C1-7烷基,或者R5和R4与它们所连接的氮原子一起形成杂环环;Y是单键、C1-7烷基、C2-7烯基或C2-7炔基;R6是卤素、杂环芳基或芳基;R′和R″各自独立地是氢、C1-7烷基-羰基或C1-7烷基;前提是当R2为H且R5为H时,R4不是取代有吗啡啶基的苯基;当NR4R5是哌嗪基时,所述的NR4R5要么未取代,要么被甲基或乙酰基取代;其药学上可接受的加合物、立体异构体、单烯氮或双烯氮、溶剂化合物或前药,用于治疗病毒感染。
  • GABAA RECEPTOR MODULATORS
    申请人:Nielsen Mogens
    公开号:US20110092525A1
    公开(公告)日:2011-04-21
    The resent invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABA A receptor modulator.
    本发明涉及具有广泛公式(I)的新化合物,作为GABAA受体调节剂在哺乳动物,包括人类中具有抗焦虑,抗惊厥,镇静催眠和肌肉松弛条件,以及焦虑,催眠和惊厥条件。
  • GABAA receptor modulators
    申请人:Nielsen Mogens Peter Cherly
    公开号:US08809355B2
    公开(公告)日:2014-08-19
    The present invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABAA receptor modulator.
    本发明涉及一种新的化合物,其通式为(I),在哺乳动物,包括人类中作为GABAA受体调节剂具有抗焦虑、抗癫痫、镇静催眠和肌肉松弛作用,同时具有焦虑、催眠和惊厥等作用。
  • 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
    申请人:Gao Ling-Jie
    公开号:US09259426B2
    公开(公告)日:2016-02-16
    This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R2 is hydrogen, NR′R″, C1-7 alkyl, arylC1-7 alkyl or C3-10 cycloalkyl; R4 is amino, C1-7 alkyl, C2-7 alkenyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted C1-7 alkyl or C3-10 cycloalkyl-C1-7 alkyl; R5 is hydrogen or C1-7 alkyl, or R5 and R4 together with the nitrogen atom to which they are attached form a heterocyclic ring; Y is a single bond, C1-7 alkylene, C2-7 alkenylene or C2-7 alkynylene; R6 is halogen, heteroaryl or aryl; R′ and R″ are each independently hydrogen, C1-7 alkyl-carbonyl or C1-7 alkyl; provided that R4 is not phenyl substituted with morpholino when R2 is H and R5 is H, and provided that when NR4R5 is piperazinyl, said NR4R5 is either non-substituted or substituted with methyl or acetyl; a pharmaceutically acceptable addition salt, a stereoisomer, a mono- or a di-N-oxide, a solvate or a pro-drug thereof, for the treatment of viral infections.
    本发明提供了由结构式(I)表示的喹唑啉衍生物;其中:R2为氢、NR′R″、C1-7烷基、芳基C1-7烷基或C3-10环烷基;R4为氨基、C1-7烷基、C2-7烯基、C3-10环烷基、C3-10环烯基、芳基、杂环、芳基烷基、杂环取代的C1-7烷基或C3-10环烷基-C1-7烷基;R5为氢或C1-7烷基,或R5与R4一起与它们所连接的氮原子形成杂环环;Y为单键、C1-7亚烷基、C2-7烯基或C2-7炔基;R6为卤素、杂环芳基或芳基;R′和R″各自独立地为氢、C1-7烷基-羰基或C1-7烷基;前提是当R2为H且R5为H时,R4不是取代了吗啡啉的苯基,且当NR4R5为哌嗪基时,所述的NR4R5要么是非取代的,要么是取代了甲基或乙酰基的;其中所述的衍生物是药学上可接受的加合盐、立体异构体、单一或二重N-氧化物、溶剂合物或前药,用于治疗病毒感染。
查看更多